Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: Tesamorelin evidence and protocol review
Also known as: TH9507
Tesamorelin is a synthetic GHRH analog and the first (and to date only) FDA-approved treatment for HIV-associated lipodystrophy, approved in 2010 as Egrifta and reformulated as Egrifta SV (2019) and the concentrated Egrifta WR. Two pooled Phase 3 randomized, double-blind, placebo-controlled trials (N=806) demonstrated a statistically significant ~15.4% reduction in visceral adipose tissue and waist circumference versus placebo at 26 weeks in HIV-infected patients with excess abdominal fat.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
1.28 mg from the EGRIFTA WR product once daily
Context: current EGRIFTA WR prescribing information
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Approved only to reduce excess abdominal fat in adults with HIV and lipodystrophy; it is not indicated for weight-loss management. The older 2 mg EGRIFTA SV presentation and current WR product are not dose-interchangeable.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Tesamorelin or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.